Search results
Drug targeting clear cell renal cell carcinoma shows promising approach
Newswise· 2 days agoApril 23, 2024 – In a groundbreaking phase one clinical trial led by UT Southwestern Medical Center,...
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 4 hours agoPatients will receive Keytruda or Keytruda plus the vaccine after bladder or kidney removal. Bladder...
Signs and Symptoms of Kidney Cancer
Health via Yahoo News· 6 days agoIn fact, kidney cancer is often found accidentally during a routine physical or imaging exam, such as an X-ray or MRI. There are three main types of kidney cancers: renal ...
Immunotherapy After Kidney Cancer Surgery Improves Overall Survival
Technology Networks· 7 days agoTreatment with pembrolizumab, an immunotherapy drug, after surgery significantly prolonged overall...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 2 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine,...
BeiGene (NASDAQ:BGNE) Trading Down 2.4%
ETF DAILY NEWS· 4 days agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report)’s stock price dropped 2.4% during trading on Friday . The company traded as low as $126.97 and last traded at $128.77. Approximately 17,319 shares ...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 16 hours agoNew York, USA, April 24, 2024 (GLOBE NEWSWIRE) -- HDAC Inhibitor Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the growth of the HDAC inhibitors market is expected
Analysts Set BeiGene, Ltd. (NASDAQ:BGNE) PT at $251.70
ETF DAILY NEWS· 3 days agoBeiGene, Ltd. (NASDAQ:BGNE – Get Free Report) has been given an average recommendation of “Moderate Buy” by the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports ...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Morningstar· 2 days agoKura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that its ...
Nisa Investment Advisors LLC Has $29,000 Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
ETF DAILY NEWS· 2 days agoNisa Investment Advisors LLC lifted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 10,740.0% during the fourth quarter, according to its most recent 13F filing with ...
